Wedbush Weighs in on Arvinas’ FY2025 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) – Stock analysts at Wedbush raised their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a note issued to investors on Wednesday, November 5th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($0.80) for the year, up from their prior forecast of ($0.88). Wedbush has a “Neutral” rating and a $9.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q4 2025 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($2.26) EPS, FY2027 earnings at ($3.97) EPS, FY2028 earnings at ($3.27) EPS and FY2029 earnings at ($3.05) EPS.

A number of other research analysts also recently issued reports on ARVN. Bank of America downgraded shares of Arvinas from a “buy” rating to a “neutral” rating and set a $10.00 price target on the stock. in a research report on Wednesday, September 24th. Guggenheim dropped their price objective on shares of Arvinas from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Arvinas in a research note on Wednesday, October 8th. BTIG Research upped their target price on Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, HC Wainwright cut their price target on Arvinas from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Eleven research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $16.34.

Arvinas Price Performance

Arvinas stock opened at $10.63 on Monday. Arvinas has a 12 month low of $5.90 and a 12 month high of $28.70. The company has a fifty day moving average price of $8.83 and a two-hundred day moving average price of $7.90. The company has a market cap of $682.66 million, a PE ratio of -13.12 and a beta of 2.38.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.27. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The business had revenue of $41.90 million for the quarter, compared to analyst estimates of $29.36 million. During the same period in the prior year, the company posted ($0.68) EPS. The business’s revenue was down 59.1% compared to the same quarter last year.

Arvinas declared that its Board of Directors has initiated a share buyback plan on Wednesday, September 17th that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 17.9% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at Arvinas

In other Arvinas news, Director Briggs Morrison purchased 30,000 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were bought at an average price of $7.57 per share, with a total value of $227,100.00. Following the completion of the acquisition, the director owned 76,021 shares in the company, valued at approximately $575,478.97. This represents a 65.19% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.73% of the company’s stock.

Hedge Funds Weigh In On Arvinas

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARVN. Alyeska Investment Group L.P. bought a new stake in Arvinas during the 1st quarter valued at $12,636,000. Vanguard Group Inc. increased its holdings in shares of Arvinas by 18.4% during the first quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company’s stock valued at $58,703,000 after purchasing an additional 1,299,639 shares during the period. Acadian Asset Management LLC raised its stake in shares of Arvinas by 791.1% during the second quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock valued at $10,498,000 after purchasing an additional 1,267,593 shares in the last quarter. Philosophy Capital Management LLC bought a new stake in shares of Arvinas during the first quarter valued at about $6,992,000. Finally, Federated Hermes Inc. lifted its holdings in Arvinas by 1,965.0% in the first quarter. Federated Hermes Inc. now owns 980,674 shares of the company’s stock worth $6,884,000 after purchasing an additional 933,183 shares during the period. 95.19% of the stock is owned by institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.